Sulfadoxine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Sulfadoxine: From Antimalarial Use to Gout
One-Sentence Summary
Sulfadoxine is a long-acting sulfonamide, historically used in combination with pyrimethamine as an antimalarial; detailed original-indication and mechanism-of-action data were not supplied in this evidence pack. The TxGNN model predicts possible efficacy in Gout, but this direction is currently supported by 0 clinical trials and only 1 tangentially related publication (a case series on toxic epidermal necrolysis, not gout). The evidence pack’s own mechanistic review flags this prediction as a likely false positive arising from shared purine-metabolism graph nodes.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not provided in evidence pack (sulfadoxine is historically a sulfonamide antimalarial, typically combined with pyrimethamine) |
| Predicted New Indication | Gout |
| TxGNN Prediction Score | 99.10% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for sulfadoxine in this evidence pack. Based on known information, sulfadoxine is a sulfonamide antifolate antimicrobial/antimalarial agent (classically paired with pyrimethamine, e.g. Fansidar) that acts via inhibition of dihydropteroate synthase in the folate synthesis pathway of susceptible organisms.
Gout is a disorder of purine/uric acid metabolism, treated by inhibiting xanthine oxidase (e.g. allopurinol) or promoting renal uric acid excretion. There is no established pharmacological link between antifolate/antibacterial activity and uric acid metabolism.
The evidence pack’s own repurposing rationale is explicit on this point: it states there is no known mechanistic connection, and that the single supporting publication (PMID 22285617, a burns-unit case series on toxic epidermal necrolysis — a severe drug reaction, not a gout treatment study) is unrelated to gout. The authors note this prediction likely reflects a spurious knowledge-graph association, possibly driven by shared “purine metabolism” nodes connecting sulfadoxine to a cluster of unrelated predictions (gout, hyperuricemia, Lesch-Nyhan syndrome) in this same evidence pack. This mechanistic implausibility should be weighed heavily against the high TxGNN score.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22285617 | 2012 | Case Series | Journal of the American Academy of Dermatology | Describes 5-year burns-unit experience treating toxic epidermal necrolysis (TEN); a severe adverse drug reaction report, not related to gout treatment |
Note: this is the only literature item associated with the gout prediction and does not provide mechanistic or clinical support for the indication.
South Africa Market Information
Sulfadoxine currently has no SAHPRA product registrations recorded in this evidence pack (0 licenses, market status: Not marketed).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no plausible mechanistic link between sulfadoxine’s antifolate/antimalarial activity and uric acid metabolism, no clinical trial evidence, and the single associated publication is unrelated to gout. The evidence pack’s own analysis identifies this as a likely spurious graph-based association rather than a genuine repurposing signal. Sulfadoxine is also not currently marketed or registered in South Africa, which is a further barrier independent of the efficacy question.
To proceed, the following is needed:
- Confirmed original indication and mechanism-of-action data for sulfadoxine (currently data gaps)
- SAHPRA-approved Professional Information (warnings, contraindications, drug interactions) — currently unavailable
- Preclinical or mechanistic studies directly linking sulfadoxine to uric acid/purine metabolism, if this direction is to be pursued further
- Independent re-evaluation of the other TxGNN-predicted indications for this drug (bronchitis, several rare congenital/genetic syndromes, diabetic nephropathy, conjunctivitis, appendicitis, peritonitis), as the same evidence pack flags most of these as similarly low-confidence or mechanistically implausible
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.